VentureBeat

TODAY’S HEADLINES:

• Breathe Tech raises $15M for respiratory disease (release)
• Protein-drug maker Pieris takes in €25M (release)
• Apthera takes in $2.1M toward cancer vaccine (VentureWire)

Breathe Tech raises $15M for respiratory disease – Breathe Technologies, a Fremont, Calif., medical device maker, raised $15 million in a second round of funding. Investors included Kleiner Perkins Caufield & Byers, Synergy Partners International, Delphi Ventures and Life Science Angels.

Breathe is developing “compact” and “lightweight” respiratory systems for the hospital and home markets, and estimates that annual sales of the devices its equipment could enhance or replace amount to $2 billion. The Breathe ventilators could be used by patients with chronic obstructive pulmonary disease, cystic fibrosis, and other lung disorders.

Protein-drug maker Pieris takes in €25M – Pieris, a German biotech pursuing a new form of protein-based drug, raised €25 million ($38 million) in a second funding round. Investors included OrbiMed Advisors, Novo Nordisk, Global Life Science Ventures, Gilde Healthcare Partners and Forbion Capital Partners.

Pieris is the latest biotech to think it can improve on monoclonal antibodies as drug candidates by developing its own engineered protein structures. The startup calls its protein structures Anticalins — they’re derived from a class of human proteins called lipocalins — and says they’re smaller and simpler than monoclonals with similar power to selectively bind to particular molecular targets.

Pieris joins a number of other companies pursuing similar strategies, including Adnexus Therapeutics, which sold itself to Bristol-Myers Squibb for $430 million, and Molecular Partners, a Swiss biotech working on modular proteins it calls DARPins. Although these are all interesting ideas, none have yet proven themselves, and all have to address a potentially significant hurdle — the fact that none of these engineered proteins are likely to engage the immune system’s disease-fighting elements the way monoclonal antibodies often do.

Apthera takes in $2.1M toward cancer vaccine – Apthera, a Scottsdale, Ariz., biotech working on therapeutic cancer vaccines, raised $2.1 million of an expected $3.9 million second funding round, VentureWire reports. Investors included the University of Texas M.D. Anderson Cancer Center, Blackmont Capital, Land Ventures and individuals.

Apthera is developing a vaccine intended to stimulate an immune response against breast-cancer cells. The startup plans to start a late-stage, phase III trial of the vaccine in the fourth quarter of this year, and hopes to raise another $10 million later this year to finance the test.

TODAY’S HEADLINES:

• Antibody-discovery startup Adimab raises new funding (release)
• Lung-device maker Spiration gets $19M (release)
• Sample-prep startup Protein Discovery pulls in $10M (release)
• Inogen takes in $13M for portable oxygen device (VentureWire)
• Healthcare IT concern Medaptus raises $11M for expansion (VentureWire)
• Contract lab Synexis raises $14M (peHUB)
• Medical-device VC firm BioStar Ventures takes in $24M of $80M fund (peHUB)
• Halsa Pharma gets $250K for “natural” obesity-control treatment (release)
• Diagnostics provider Lab21 acquires NPTech (peHUB)
• Galil Medical names Martin Emerson CEO (release)

Antibody-discovery startup Adimab raises new funding – Lebanon, N.H.-based Adimab, a biotech working on new ways to discover antibody drugs, has raised a second round of funding. The company didn’t disclose the size of the round.

Adimab, which raised $6 million last July, is one of several startups looking to design new antibody drugs in bioengineered yeast cells, as we wrote at the time. (Alder Biopharmaceuticals, which raised $40 million in January, is another.) The technique promises to be much faster — and freer of patent restrictions — than current methods. When Adimab completes its current manufacturing facility in the second quarter, it claims it will be able to produce a panel of human antibodies against a particular target in just 90 days, instead of the year or more traditional methods can require.

Investors included Polaris Venture Partners and SV Life Sciences, who also invested in the company’s first round.

Lung-device maker Spiration gets $19M – Spiration, a Redmond, Wash., medical-device startup, raised $18.5 million in a seventh funding round. Investors included Versant Ventures, Olympus Medical Systems, New Enterprise Associates, New Leaf Venture Partners, InterWest Partners, Investor Growth Capital and Three Arch Partners.

Spiration has now raised a total of $97 million. It is developing a set of one-way valves for emphysema that can be implanted in the lung’s airways via a minimally invasive procedure. These valves are designed to shunt air away from diseased portions of the lung and redirect it to healthier areas. The company said the funding would support commercialization of its device in Europe and to complete studies for regulatory approval in the U.S.

Other startups working on similar technology include Emphasys Medical, Pulmonx and Broncus Technologies.

Sample-prep startup Protein Discovery pulls in $10M – Knoxville, Tenn.-based Protein Discovery, a biotech with new laboratory technology for protein identification, raised $10 million in a third funding round. Investors included Santé Ventures, Memphis Biomed Ventures, the Southern Appalachian Fund, and the Nashville Capital Network.

The startup is developing technology that aims to “simplify” the process of preparing biological samples for protein analysis. The details are probably too much for anyone who’s not a lab technician themselves, but feel free to check out the company’s explanation if you dare.)

Inogen takes in $13M for portable oxygen device – Inogen, a Goleta, Calif., medical-device maker, raised $12.6 million in its fifth funding round, VentureWire reports. Investors included Accuitive Medical Ventures, Arboretum Ventures, Avalon Ventures, Novo A/S, Numenor Ventures and Versant Ventures.

The company makes and sells portable oxygen-delivery systems for patients suffering from a lung problem called chronic obstructive pulmonary disease. The product has been on the market for several years, and Inogen says it believes it might take several more before it’s in a position to be acquired or to go public.

MAP Pharmaceuticals, the Mountain View, Calif., specialty pharma, had a mixed reception to its IPO Friday. The company priced its shares at $12, below its anticipated range of $14 to $16, raising up to $69 million — substantially less than the $92 million it might have pulled in. Investors, however, reacted positively and pushed up the shares 11 percent to $13.35.

MAP reformulates existing drugs in order to deliver them via inhalers. Its leading product is a new version of the asthma drug budesonide, which is used to treat pediatric asthma. See our previous coverage of the company here (second item) and here.

Some other recent filings that slipped through the cracks:

Anti-infective developer Anacor Pharma looks for $58M IPO — Palo Alto, Calif.-based Anacor Pharmaceuticals, a biotech developing new antibiotics, anti-inflammatories and antifungal drugs, filed to raise up to $57.5 million in an IPO on Aug. 31. The company, which develops new drugs from a process focused on the chemistry of boron, is focused first on topical medications for fungal nail infections known as onychomycosis and the autoimmune skin condition psoriasis. See our previous coverage of the company here.

Emphasys Medical targets $86M IPO for lung devices — Redwood City, Calif.-based Emphasys Medical, a device maker focused on treatments for emphysema and similar lung diseases, filed on Sept. 21 to raise up to $86.3 million in an IPO. The company makes insertable one-way valves for the bronchial tubes that move air in and out of the lungs; these valves can “close off” diseased and overinflated parts of the lung in order to enable the remaining healthy areas to function normally.

As part of its SEC filing, Emphasys also disclosed the results of a pivotal trial of its device, known as the Emphasys Bronchial Valve, or EBV. In that randomized trial of 321 patients, those who received the EBV saw exhaled air volume — a sign of lung health — 6.4 percent greater than that of untreated patients. Patients treated with the device were also able to walk 5.6 percent farther in six minutes than the control group.

Drug formulator MonoSol Rx sets IPO price range, hopes for $83M — MonoSol Rx, a Warren, N.J., maker of drug formulations designed to mask the taste of particular medications, says it hopes to raise up to $82.8 million in an IPO. The company plans to sell up to 4.6 million shares at a price of $16 to $18 apiece, it said in a filing on Oct. 3. MonoSol Rx makes quick-dissolving “thin films” that can be used to repackage existing drugs into easy-to-swallow forms.

Irish reformulator Merrion Pharma hopes for $55M IPO — Dublin’s Merrion Pharmaceuticals, a developer of drug formulations that improve absorption within the gastrointestinal tract, aims to raise up to $55.2 million in an IPO. The company plans to offer four million shares as American Depositary Shares at a price of $10 to $12 apiece. Merrion’s technology is designed to reformulate drugs that can only be injected into pill or gel capsule forms.

(UPDATED at 5:55pm PT: See below.)

Featured companies: Sierra Surgical Technologies, HerbalScience Nutraceuticals, Topigen Pharmaceuticals, EKR Therapeutics, Molecular Partners, Celsense, Glucose Sensing Technologies, Falcon Genomics, Waters, Calorimetry Sciences, Parion Sciences, Gilead Sciences, Isto Technologies, Fluidnet, NABsys

Sierra Surgical raises $7.1M — Palo Alto, Calif.-based Sierra Surgical Technologies, a developer of female sterilization technology, raised $7.1 million in a first funding round, PE Hub reports, citing a regulatory filing. Alta Partners and De Novo Ventures provided the funding.

Singapore’s HerbalScience raises $28M for natural extracts — HerbalScience Nutraceuticals, a Singapore-based natural-extracts company with offices in Naples, Fla., raised $28 million from the private-equity firms Aisling Capital and Weston Presidio, VentureWire reports (subscription required). The investment purchased a 25 percent stake in HerbalSciences, which makes purified extracts from various natural substances, valuing the company at $112 million.

Topigen Pharma pulls in $25M against lung disease — Montreal’s Topigen Pharmaceuticals, a biotech developing inhalable drugs to treat asthma and other lung diseases, raised $25 million (C$26 million) in a third funding round. Investors included NovaQuest, MMV Financial, BDC Venture Capital, Desjardins Venture Capital, Caisse de Dépot et Placement du Québec (Caisse), T2C2/BIO 2000 and Lothian Partners 27 (sarl) SICAR.

The funding will “accelerate” mid-stage human trials for Topigen’s leading drug candidates, a small-molecule treatment for chronic obstructive pulmonary disease and an RNA inhibitor for asthma.

EKR receives over $13M, licenses opiod drug — EKR Therapeutics, a Cedar Knolls, N.J., specialty pharmaceutical company, raised more than $13 million in a private placement. Investors included Quaker BioVentures, NewSpring Capital, and ESP Equity Partners. EKR also acquired rights to DepoDur, an extended-release opioid, from Pacira Pharmaceuticals.

Switzerland’s Molecular Partners gets $15.6M for novel binding proteins — Zurich-based Molecular Partners, a biotech developing drugs based on a new class of binding proteins, raised $15.6 million (CHF18.5 million) in a first funding round. Investors included Index Ventures, BB Biotech Ventures, Johnson & Johnson Development Corp. and Endeavour.

Molecular Partners is focused on developing therapeutics proteins it calls “DARPins,” which the company says offer the same ability to stick selectively to other molecules as monoclonal antibodies, but with greater stability and ease of manufacturing. DARPins are based on the notion of “repeat proteins,” which as the name suggests are modular proteins that contain repeated elements — something like posts spaced at regular intervals along a barbed-wire fence. (See the image at left.) The protein itself ends up looking something like a string that’s been knotted at regular intervals, only much more complicated.

Repeat proteins are found in almost all species, and in nature serve to bind other proteins in order to facilitate protein-protein reactions. By shuffling the modular elements in these proteins, they can be engineered to stick to specific molecules such as cell-surface proteins, potentially making them useful as drugs. The company has a more detailed description here.

Although Molecular Partners likes to play up the advantages of DARPins (the acronym stands for “designed ankyrin repeat proteins”) over antibodies — here, for instance — there are a few disadvantages the company doesn’t mention. As large molecules, DARPins most likely won’t get inside cells, limiting their potential as drugs to interactions with free-floating and cell-surface proteins. (Monoclonal antibodies have the same limitation.) Potentially more important, however, is the fact that the effectiveness of many antibody-based drugs results from their ability to stimulate a particular immune response, not just to stick to the appropriate target. DARPins, which aren’t immune-system molecules the way antibodies are, seem unlikely to do the same.

Pittsburgh-area biotechs, device makers get $350K — The Pittsburgh Life Sciences Greenhouse, a public-private life-sciences investment partnership, invested $350,000 in three Pittsburgh-area life-science startups. Falcon Genomics, a developer of chip-based cancer-detection diagnostics, received $150,000. Another $100,000 went to Celsense, which uses an MRI tracing agent to image transplanted cells. The final $100,000 was invested in Glucose Sensing Technologies, which is developing a catheter-based glucose sensor for continuous blood-sugar monitoring in intensive-care units.

Waters acquires Calorimetry Sciences — Milford, Mass.-based Waters, a laboratory-instrument maker, acquired Calorimetry Sciences of Linden, Utah. Terms of the deal weren’t announced. Calorimetry Sciences, which makes high-performance devices intended to measure the heat produced or absorbed by chemical reactions, will be merged into Waters’ TA Instruments division.

Fedora Commons wins $4.9M grant for open collaboration software — Fedora Commons, a non-profit organization devoted to open-source technologies for creating and sharing digital content, received a $4.9 million grant from the Gordon and Betty Moore Foundation. From the release:

With this funding, Fedora Commons will foster an open community to support the development and deployment of open source software, which facilitates open collaboration and open access to scholarly, scientific, cultural, and educational materials in digital form. The software platform developed by Fedora Commons with Gordon and Betty Moore Foundation funding will support a networked model of intellectual activity, whereby scientists, scholars, teachers, and students will use the Internet to collaboratively create new ideas, and build on, annotate, and refine the ideas of their colleagues worldwide. With its roots in the Fedora open-source repository system, developed since 2001 with support from the Andrew W. Mellon Foundation, the new software will continue to focus on the integrity and longevity of the intellectual products that underlie this new form of knowledge work. The result will be an open source software platform that both enables collaborative models of information creation and sharing, and provides sustainable repositories to secure the digital materials that constitute our intellectual, scientific, and cultural history.

Parion licenses lung-disease drug to Gilead for up to $146M — Parion Sciences, a Durham, N.C., biotech focused on diseases of the mucous membranes, struck a licensing and co-development deal with Gilead Sciences for its drug P-680 worth up to $146 million. The drug, an epithelial sodium-channel inhibitor, could potentially be useful in a variety of lung diseases, including cystic fibrosis. The companies will also work to identify other similar drug candidates.

Isto Tech raises $8.8M, prepares to launch synthetic bone grafts — St. Louis’ Isto Technologies, a developer of cell-based cartilage and bone regeneration technology, raised $8.8 million in a fifth funding round as it prepares for its first product launch, VentureWire reports. Investors included Ascension Health Ventures, Alafi Capital, Life Sciences Partners, Mid-America Transplant Services and private individuals. Isto’s leading product, InQu, is a synthetic biomaterial intended to help tissues heal and bones to regenerate; Isto expects FDA approval later this year.

Fluidnet rises from ashes, raises $6.4M for IV pumps — Portsmouth, N.H.-based Fluidnet, a “reincarnation” of its bankrupt predecessor FluidSense, raised $6.4 million in a first funding round to launch a new intravenous-infusion pump next year, VentureWire reports. Cardinal Partners and Rockport Venture Partners provided the funding.

NABsys raises $750K for high-speed genome sequencing — NABsys, a Providence, R.I., startup focused on high-speed gene-sequencing technologies, raised $750,000 in seed funding, VentureWire reports. Slater Technology Fund and individual investors provided the funding, which closely follows a $1.3 million grant from the National Institutes of Health.

UPDATE (10:55am PT): Added items on Molecular Partners and the Pittsburgh Life-Sciences Greenhouse investments.

UPDATE REDUX (5:55 pm PT): Added items on Waters/Calorimetry Sciences, Fedora Commons, Isto Technologies, Fluidnet, NABsys.